Loading...
Docoh
Log in Free sign up

Nymox Pharmaceutical (NYMX)

Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.

Company profile

Ticker
NYMX
Exchange
NASDAQ
Website
nymox.com
CEO
Paul Averback
Employees
Location
Quebec, Canada
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
In Vitro & In Vivo Diagnostic Substances
Ortho Clinical Diagnostics • QuidelOrtho • Idexx Laboratories • Myriad Genetics • Neogen • Lantheus • QuidelOrtho • Meridian Bioscience • Celldex Therapeutics • Achieve Life Sciences ...
SEC CIK
0001018735
Corporate docs

NYMX stock data

News

From Benzinga Pro
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
12 Aug 22
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
12 Health Care Stocks Moving In Thursday's Intraday Session
11 Aug 22
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session
11 Aug 22
Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering.
11 Health Care Stocks Moving In Monday's Pre-Market Session
25 Jul 22
12 Health Care Stocks Moving In Friday's After-Market Session
22 Jul 22

Press releases

From Benzinga Pro
NYMOX Updates Shareholders
15 Jul 22
IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced an update to its shareholders regarding progress in the Company business activities. Nymox wishes to
NYMOX Receives Deficiency Letter from NASDAQ
14 Jul 22
IRVINE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reports that on July 7, 2022 the Company received a deficiency letter from NASDAQ stating that the Company is no longer

Calendar

30 Mar 22
12 Aug 22
31 Dec 22

Financial summary

Financial statements Chart NYMX financial data
Quarter (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Financial data from company earnings reports.

Recent insider trades

NYMX insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 May 22 Robinson James George Common Stock Buy Acquire P No No 1.65 1,151,515 1.9M 4,702,065
2 May 22 Robinson James George Warrant Common stock Buy Acquire P No No 2 1,151,515 2.3M 1,151,515
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.085 200 417 3,550,550
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.0882 1,100 2.3K 3,550,350
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.0899 2,900 6.06K 3,549,250
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.1 800 1.68K 3,546,350
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.08 51 106.08 3,545,550
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.0899 4,949 10.34K 3,545,499
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.05 5,000 10.25K 3,540,550
22 Apr 21 Robinson James George Common Stock Buy Acquire P No No 2.105 3,100 6.53K 3,535,550
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q3 2021

NYMX institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Quest Diagnostics • Orasure

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: alter, anniversary, Aveback, communicated, communicating, communication, concurrent, Culter, customary, exemplary, ID, issuable, reclassified, reward, thousand
Removed: waived
From filing 20-F 2021 FY
Financial reports
View all
20-F
2021 FY
Annual report (foreign)
30 Mar 22
20-F/A
2020 FY
Annual report (foreign) (amended)
11 Jun 21
20-F
2020 FY
Annual report (foreign)
29 Mar 21
20-F
2019 FY
Annual report (foreign)
30 Mar 20
20-F
2018 FY
Annual report (foreign)
29 Mar 19
20-F/A
2017 FY
Annual report (foreign) (amended)
11 May 18
20-F
2017 FY
Annual report (foreign)
29 Mar 18
20-F
2016 FY
Annual report (foreign)
30 Mar 17
20-F
2015 FY
Annual report (foreign)
30 Mar 16
20-F
2014 FY
Annual report (foreign)
30 Mar 15
Current reports
View all
6-K
Current report (foreign)
7 Jul 22
6-K
2022 Q1
Current report (foreign)
13 May 22
6-K
Nymox Announces Closing of $6.4 Million Registered Direct Offering
22 Mar 22
6-K/A
Notice of the Annual General Meeting of the Shareholders
22 Nov 21
6-K
Notice of the Annual General Meeting of the Shareholders
19 Nov 21
6-K
2021 Q3
Current report (foreign)
12 Nov 21
6-K
2021 Q2
Current report (foreign)
13 Aug 21
6-K
2021 Q1
Current report (foreign)
14 May 21
6-K
Nymox Announces $8,000,000 Private Placement
6 May 21
6-K
Notice of the Annual General Meeting of the Shareholders
20 Nov 20
Registration and prospectus
View all
F-3
Shelf registration (foreign)
29 Mar 22
424B5
Prospectus supplement for primary offering
22 Mar 22
F-3
Shelf registration (foreign)
9 Dec 21
F-3
Shelf registration (foreign)
11 May 21
424B5
Prospectus supplement for primary offering
14 Aug 20
424B5
Prospectus supplement for primary offering
13 Aug 20
424B5
Prospectus supplement for primary offering
17 Jul 20
F-3
Shelf registration (foreign)
3 Apr 20
424B5
Prospectus supplement for primary offering
8 Feb 16
F-3
Shelf registration (foreign)
13 Jul 15
Proxies
No filings
Other
View all
EFFECT
Notice of effectiveness
13 Apr 22
CORRESP
Correspondence with SEC
5 Apr 22
UPLOAD
Letter from SEC
3 Apr 22
EFFECT
Notice of effectiveness
31 Jan 22
CORRESP
Correspondence with SEC
24 Jan 22
UPLOAD
Letter from SEC
21 Dec 21
EFFECT
Notice of effectiveness
21 May 21
CORRESP
Correspondence with SEC
16 May 21
UPLOAD
Letter from SEC
13 May 21
EFFECT
Notice of effectiveness
13 May 20
Ownership
View all
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
6 May 22
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
27 Apr 21
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
12 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
10 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
9 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
3 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
2 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
1 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
28 Jun 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
27 Jun 19

Patents

View all
Utility
Method of Enhancing the Therapeutic Efficacy of Fexapotide Triflutate In Treating Luts
21 Jul 22
Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year.
Utility
Focal treatment of prostate cancer
17 May 22
The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.
Utility
Method of treating lower urinary tract symptoms with fexapotide triflutate
22 Mar 22
Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient.
Utility
Methods of treating multifocal cancer
25 Jan 22
The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.
Utility
Focal Treatment of Prostate Cancer
4 Feb 21
The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.

Reddit threads

View all